Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | QPCT | Q16769 | 1/20 | 0.54 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.54 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35352 | 0.97 | CYP19A1 (0.56) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL27713045 | 0.95 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| SCHEMBL27828239 | 0.95 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| Pyridine SCHEMBL27715231 | 0.84 | CYP11B1 (0.60) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| SCHEMBL27843590 | 0.84 | CYP19A1 (0.46) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| Thiophene SCHEMBL28885754 | 0.84 | CYP19A1 (0.46) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| Cyanate SCHEMBL27832718 | 0.84 | CYP1A2 (0.46) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| SCHEMBL9765618 | 0.83 | CYP11B1 (0.61) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| SCHEMBL3361305 | 0.83 | CYP11B1 (0.53) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 | |
| SCHEMBL11430510 | 0.78 | NPC1 (0.65) | CYP19A1CYP11B1CYP11B2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4035668-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2019033068-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | WO | disclosed |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | SIGMAR1 1829/4885CYP19A1 4532/4885CYP11B1 4571/4885 |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | SIGMAR1 64/4885CYP19A1 3491/4885CYP11B1 1540/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | SIGMAR1 64/4885CYP19A1 3491/4885CYP11B1 1540/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | SIGMAR1 1990/4885CYP19A1 4547/4885CYP11B1 4290/4885 |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHRM2, CHRM1, CHRM4 | SIGMAR1 81/4885CYP19A1 3806/4885CYP11B1 2988/4885 |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | SIGMAR1 211/4885CYP19A1 1561/4885CYP11B1 2935/4885 |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | ACHE, BCHE, CHAT | SIGMAR1 411/4885CYP19A1 559/4885CYP11B1 2454/4885 |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | SIGMAR1 119/4885CYP19A1 3826/4885CYP11B1 2465/4885 |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | SIGMAR1 119/4885CYP19A1 3826/4885CYP11B1 2465/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | SIGMAR1 1643/4885CYP19A1 4553/4885CYP11B1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.